Blonder Tongue Laboratories, Inc. Logo

Blonder Tongue Laboratories, Inc.

BDR

(1.2)
Stock Price

0,31 USD

-4.45% ROA

216.36% ROE

-6.64x PER

Market Cap.

0,00 USD

-5.13% DER

0% Yield

-10.5% NPM

Blonder Tongue Laboratories, Inc. Stock Analysis

Blonder Tongue Laboratories, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Blonder Tongue Laboratories, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.92x) suggests it's undervalued, making it an attractive opportunity for investors.

2 ROE

ROE in an average range (3.72%) suggests satisfactory profitability and decent utilization of shareholders' equity.

3 ROA

The stock's ROA (0.84%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

5 DER

The company has a high debt to equity ratio (106%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-512) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Blonder Tongue Laboratories, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Blonder Tongue Laboratories, Inc. Technical Stock Analysis
# Analysis Recommendation

Blonder Tongue Laboratories, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Blonder Tongue Laboratories, Inc. Revenue
Year Revenue Growth
1995 52.000.000
1996 48.900.000 -6.34%
1997 62.100.000 21.26%
1998 70.800.000 12.29%
1999 56.805.000 -24.64%
2000 70.196.000 19.08%
2001 53.627.000 -30.9%
2002 46.951.000 -14.22%
2003 35.437.000 -32.49%
2004 39.233.000 9.68%
2005 36.468.000 -7.58%
2006 35.775.000 -1.94%
2007 33.159.000 -7.89%
2008 35.320.000 6.12%
2009 29.034.000 -21.65%
2010 30.508.000 4.83%
2011 26.663.000 -14.42%
2012 30.643.000 12.99%
2013 27.870.000 -9.95%
2014 29.129.000 4.32%
2015 20.943.000 -39.09%
2016 22.506.000 6.94%
2017 23.283.000 3.34%
2018 21.707.000 -7.26%
2019 19.842.000 -9.4%
2020 16.379.000 -21.14%
2021 15.754.000 -3.97%
2022 21.112.000 25.38%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Blonder Tongue Laboratories, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1995 0
1996 2.000.000 100%
1997 2.000.000 0%
1998 2.200.000 9.09%
1999 2.070.000 -6.28%
2000 2.125.000 2.59%
2001 2.200.000 3.41%
2002 1.972.000 -11.56%
2003 1.833.000 -7.58%
2004 1.549.000 -18.33%
2005 1.552.000 0.19%
2006 1.634.000 5.02%
2007 1.797.000 9.07%
2008 1.989.000 9.65%
2009 2.420.000 17.81%
2010 2.508.000 3.51%
2011 2.716.000 7.66%
2012 3.500.000 22.4%
2013 3.373.000 -3.77%
2014 3.416.000 1.26%
2015 3.331.000 -2.55%
2016 2.741.000 -21.52%
2017 2.452.000 -11.79%
2018 2.576.000 4.81%
2019 3.066.000 15.98%
2020 2.524.000 -21.47%
2021 2.592.000 2.62%
2022 1.428.000 -81.51%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Blonder Tongue Laboratories, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 11.800.000
1996 9.100.000 -29.67%
1997 9.900.000 8.08%
1998 10.800.000 8.33%
1999 13.598.000 20.58%
2000 13.572.000 -0.19%
2001 11.209.000 -21.08%
2002 9.060.000 -23.72%
2003 9.837.000 7.9%
2004 10.269.000 4.21%
2005 11.023.000 6.84%
2006 10.396.000 -6.03%
2007 9.548.000 -8.88%
2008 4.935.000 -93.48%
2009 4.669.000 -5.7%
2010 4.597.000 -1.57%
2011 4.410.000 -4.24%
2012 5.635.000 21.74%
2013 5.111.000 -10.25%
2014 4.770.000 -7.15%
2015 4.152.000 -14.88%
2016 3.828.000 -8.46%
2017 3.529.000 -8.47%
2018 4.236.000 16.69%
2019 5.004.000 15.35%
2020 5.150.000 2.83%
2021 3.767.000 -36.71%
2022 3.584.000 -5.11%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Blonder Tongue Laboratories, Inc. EBITDA
Year EBITDA Growth
1995 6.800.000
1996 7.600.000 10.53%
1997 11.800.000 35.59%
1998 13.400.000 11.94%
1999 3.055.000 -338.63%
2000 8.588.000 64.43%
2001 4.733.000 -81.45%
2002 -4.417.000 207.15%
2003 -1.557.000 -183.69%
2004 1.435.000 208.5%
2005 -3.843.000 137.34%
2006 1.957.000 296.37%
2007 -66.000 3065.15%
2008 477.000 113.84%
2009 919.000 48.1%
2010 2.812.000 67.32%
2011 913.000 -208%
2012 -1.057.000 186.38%
2013 -1.231.000 14.13%
2014 786.000 256.62%
2015 -5.092.000 115.44%
2016 -194.000 -2524.74%
2017 963.000 120.15%
2018 -895.000 207.6%
2019 -7.254.000 87.66%
2020 -6.783.000 -6.94%
2021 -2.620.000 -158.89%
2022 1.392.000 288.22%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Blonder Tongue Laboratories, Inc. Gross Profit
Year Gross Profit Growth
1995 19.900.000
1996 19.400.000 -2.58%
1997 23.600.000 17.8%
1998 27.900.000 15.41%
1999 20.725.000 -34.62%
2000 26.223.000 20.97%
2001 16.699.000 -57.03%
2002 12.756.000 -30.91%
2003 9.489.000 -34.43%
2004 12.602.000 24.7%
2005 8.304.000 -51.76%
2006 12.366.000 32.85%
2007 11.309.000 -9.35%
2008 11.607.000 2.57%
2009 11.276.000 -2.94%
2010 12.265.000 8.06%
2011 9.541.000 -28.55%
2012 10.018.000 4.76%
2013 9.311.000 -7.59%
2014 10.961.000 15.05%
2015 4.155.000 -163.8%
2016 8.357.000 50.28%
2017 8.936.000 6.48%
2018 8.419.000 -6.14%
2019 3.431.000 -145.38%
2020 3.018.000 -13.68%
2021 5.858.000 48.48%
2022 8.224.000 28.77%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Blonder Tongue Laboratories, Inc. Net Profit
Year Net Profit Growth
1995 5.500.000
1996 3.900.000 -41.03%
1997 6.400.000 39.06%
1998 7.100.000 9.86%
1999 59.000 -11933.9%
2000 3.576.000 98.35%
2001 1.217.000 -193.84%
2002 -6.457.000 118.85%
2003 -2.749.000 -134.89%
2004 -3.122.000 11.95%
2005 -5.500.000 43.24%
2006 342.000 1708.19%
2007 -561.000 160.96%
2008 -411.000 -36.5%
2009 75.000 648%
2010 1.785.000 95.8%
2011 -411.000 534.31%
2012 -5.157.000 92.03%
2013 -2.822.000 -82.74%
2014 -902.000 -212.86%
2015 -6.771.000 86.68%
2016 -1.195.000 -466.61%
2017 -384.000 -211.2%
2018 -1.339.000 71.32%
2019 -742.000 -80.46%
2020 -7.474.000 90.07%
2021 84.000 8997.62%
2022 360.000 76.67%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Blonder Tongue Laboratories, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 1
1996 0 0%
1997 1 0%
1998 1 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 -1 0%
2003 0 0%
2004 0 0%
2005 -1 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 0 0%
2014 0 0%
2015 -1 100%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 -1 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Blonder Tongue Laboratories, Inc. Free Cashflow
Year Free Cashflow Growth
1995 -5.600.000
1996 -2.000.000 -180%
1997 900.000 322.22%
1998 -19.000.000 104.74%
1999 6.186.000 407.15%
2000 5.888.000 -5.06%
2001 2.908.000 -102.48%
2002 562.000 -417.44%
2003 4.732.000 88.12%
2004 3.276.000 -44.44%
2005 1.655.000 -97.95%
2006 -417.000 496.88%
2007 1.640.000 125.43%
2008 748.000 -119.25%
2009 -1.794.000 141.69%
2010 1.931.000 192.91%
2011 -633.000 405.06%
2012 3.538.000 117.89%
2013 1.707 -207164.21%
2014 942 -81.21%
2015 -986 195.54%
2016 734 234.33%
2017 -375 295.73%
2018 506 174.11%
2019 -6.801 107.44%
2020 -3.377 -101.39%
2021 -1.198 -181.89%
2022 197.000 100.61%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Blonder Tongue Laboratories, Inc. Operating Cashflow
Year Operating Cashflow Growth
1995 -100.000
1996 -500.000 80%
1997 2.300.000 121.74%
1998 900.000 -155.56%
1999 7.383.000 87.81%
2000 6.256.000 -18.01%
2001 3.711.000 -68.58%
2002 1.257.000 -195.23%
2003 5.686.000 77.89%
2004 3.915.000 -45.24%
2005 2.646.000 -47.96%
2006 72.000 -3575%
2007 2.095.000 96.56%
2008 1.281.000 -63.54%
2009 -1.328.000 196.46%
2010 3.071.000 143.24%
2011 239.000 -1184.94%
2012 3.640.000 93.43%
2013 1.861 -195493.77%
2014 1.615 -15.23%
2015 -798 302.38%
2016 771 203.5%
2017 -237 425.32%
2018 587 140.37%
2019 -6.538 108.98%
2020 -3.212 -103.55%
2021 -1.167 -175.24%
2022 210.000 100.56%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Blonder Tongue Laboratories, Inc. Capital Expenditure
Year Capital Expenditure Growth
1995 5.500.000
1996 1.500.000 -266.67%
1997 1.400.000 -7.14%
1998 19.900.000 92.96%
1999 1.197.000 -1562.49%
2000 368.000 -225.27%
2001 803.000 54.17%
2002 695.000 -15.54%
2003 954.000 27.15%
2004 639.000 -49.3%
2005 991.000 35.52%
2006 489.000 -102.66%
2007 455.000 -7.47%
2008 533.000 14.63%
2009 466.000 -14.38%
2010 1.140.000 59.12%
2011 872.000 -30.73%
2012 102.000 -754.9%
2013 154 -66133.77%
2014 673 77.12%
2015 188 -257.98%
2016 37 -408.11%
2017 138 73.19%
2018 81 -70.37%
2019 263 69.2%
2020 165 -59.39%
2021 31 -432.26%
2022 13.000 99.76%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Blonder Tongue Laboratories, Inc. Equity
Year Equity Growth
1995 19.700.000
1996 25.600.000 23.05%
1997 31.800.000 19.5%
1998 40.500.000 21.48%
1999 35.247.000 -14.9%
2000 39.096.000 9.84%
2001 39.962.000 2.17%
2002 33.267.000 -20.13%
2003 31.940.000 -4.15%
2004 26.923.000 -18.63%
2005 21.499.000 -25.23%
2006 20.232.000 -6.26%
2007 20.677.000 2.15%
2008 19.436.000 -6.39%
2009 20.155.000 3.57%
2010 22.043.000 8.57%
2011 21.203.000 -3.96%
2012 16.625.000 -27.54%
2013 15.028.000 -10.63%
2014 13.738.000 -9.39%
2015 7.369.000 -86.43%
2016 6.534.000 -12.78%
2017 7.413.000 11.86%
2018 7.167.000 -3.43%
2019 -19.910.000 136%
2020 -27.382.000 27.29%
2021 -27.297.000 -0.31%
2022 -30.217.000 9.66%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Blonder Tongue Laboratories, Inc. Assets
Year Assets Growth
1995 31.800.000
1996 36.200.000 12.15%
1997 42.300.000 14.42%
1998 69.700.000 39.31%
1999 66.076.000 -5.48%
2000 62.834.000 -5.16%
2001 64.386.000 2.41%
2002 52.002.000 -23.81%
2003 47.990.000 -8.36%
2004 38.156.000 -25.77%
2005 32.864.000 -16.1%
2006 27.222.000 -20.73%
2007 25.949.000 -4.91%
2008 27.042.000 4.04%
2009 25.172.000 -7.43%
2010 26.612.000 5.41%
2011 25.871.000 -2.86%
2012 26.303.000 1.64%
2013 22.641.000 -16.17%
2014 21.244.000 -6.58%
2015 16.230.000 -30.89%
2016 15.000.000 -8.2%
2017 15.174.000 1.15%
2018 15.601.000 2.74%
2019 18.347.000 14.97%
2020 11.130.000 -64.84%
2021 11.910.000 6.55%
2022 15.005.000 20.63%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Blonder Tongue Laboratories, Inc. Liabilities
Year Liabilities Growth
1995 12.100.000
1996 10.600.000 -14.15%
1997 10.500.000 -0.95%
1998 29.200.000 64.04%
1999 30.829.000 5.28%
2000 23.738.000 -29.87%
2001 24.424.000 2.81%
2002 18.735.000 -30.37%
2003 16.050.000 -16.73%
2004 11.233.000 -42.88%
2005 11.365.000 1.16%
2006 6.990.000 -62.59%
2007 5.272.000 -32.59%
2008 7.606.000 30.69%
2009 5.017.000 -51.6%
2010 4.569.000 -9.81%
2011 4.668.000 2.12%
2012 9.678.000 51.77%
2013 7.613.000 -27.12%
2014 7.506.000 -1.43%
2015 8.861.000 15.29%
2016 8.466.000 -4.67%
2017 7.761.000 -9.08%
2018 8.434.000 7.98%
2019 8.369.000 -0.78%
2020 9.893.000 15.4%
2021 8.625.000 -14.7%
2022 13.931.000 38.09%

Blonder Tongue Laboratories, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.79
Net Income per Share
-0.05
Price to Earning Ratio
-6.64x
Price To Sales Ratio
0x
POCF Ratio
-407.08
PFCF Ratio
0
Price to Book Ratio
-0.13
EV to Sales
-0.01
EV Over EBITDA
0.75
EV to Operating CashFlow
7.9
EV to FreeCashFlow
1.93
Earnings Yield
-0.15
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
1.53
Graham NetNet
-0.89

Income Statement Metrics

Net Income per Share
-0.05
Income Quality
0.02
ROE
0.02
Return On Assets
-0.11
Return On Capital Employed
-0.15
Net Income per EBT
1.01
EBT Per Ebit
1.83
Ebit per Revenue
-0.06
Effective Tax Rate
-0.37

Margins

Sales, General, & Administrative to Revenue
0.18
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.31
Operating Profit Margin
-0.06
Pretax Profit Margin
-0.1
Net Profit Margin
-0.11

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
3.1
Capex to Revenue
-0
Capex to Depreciation
-0.08
Return on Invested Capital
0.01
Return on Tangible Assets
-0.04
Days Sales Outstanding
0
Days Payables Outstanding
125.4
Days of Inventory on Hand
204.58
Receivables Turnover
0
Payables Turnover
2.91
Inventory Turnover
1.78
Capex per Share
-0

Balance Sheet

Cash per Share
0,01
Book Value per Share
-2,26
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
-2.26
Interest Debt per Share
0.15
Debt to Equity
-0.05
Debt to Assets
0.1
Net Debt to EBITDA
0.75
Current Ratio
0.98
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-0.05
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.08
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
4062000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Blonder Tongue Laboratories, Inc. Dividends
Year Dividends Growth

Blonder Tongue Laboratories, Inc. Profile

About Blonder Tongue Laboratories, Inc.

Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television (TV) signal encoding, transcoding, digital transport, and broadband product solutions in the United States. It offers encoders/transcoders, such as 4K/ultra-high definition, high definition and standard definition, MPEG-2, MPEG-4/H.264, and HEVC/H.265 capable encoders and transcoders; and QPSK and 8PSK, and QAM transcoders. The company also provides NXG IP digital video processing and headend products, including IPTV format conversions and simulcast use cases. In addition, it offers coax distribution products comprising broadband amplifiers, directional taps, splitters, and wall outlets; coax distribution products are either mounted on exterior utility poles or encased in pedestals, vaults, or other security devices in cable television systems; distribution system is enclosed within the walls of the building or added to an existing structure using various techniques to hide the coax cable and devices in SMB systems; and non-passive devices for signal distributed from the headend is of sufficient strength when it arrives at its final destination to provide audio/video images. Further, the company provides CPE products consisting of Android-based IPTV set top boxes. Additionally, it offers digital modulation products, such as Aircastertm ATSC, QAM, and IP trans-modulator series of products allow the user to create a line up from off-air and/or cable feeds for coax IP distribution; Edge QAM devices that accept Ethernet input and capture MPEG over IP transport streams, decrypt service provider conditional access or content protection, and insert proprietary conditional access; DOCSIS data products; service level agreements and services; and analog modulation, fiber, and miscellaneous products and services, as well as test and measurement instruments, and contract manufacturing services. The company was founded in 1950 and is headquartered in Old Bridge, New Jersey.

CEO
Mr. Edward Grauch
Employee
84
Address
1 Jake Brown Rd, PO Box 1000
Old Bridge, 08857

Blonder Tongue Laboratories, Inc. Executives & BODs

Blonder Tongue Laboratories, Inc. Executives & BODs
# Name Age

Blonder Tongue Laboratories, Inc. Competitors